BioOhio Board of Trustees
BioOhio is proud to have a board comprised of some of the most influential leaders in Ohio’s bioscience community. From all corners of the state, and representing many business elements within the life cycle of a company, this leadership assists BioOhio accomplish its mission.
Geoff Morgan, BioOhio Board Chair, Vice President & General Manager, Quidel
Geoff has been with Quidel/Diagnostic Hybrids since 2003, serving as Vice President and Chief Financial Officer, and most recently as Vice President and General Manager. Prior to Quidel, Geoff was with Blue Chip Broadcasting and PricewaterhouseCoopers, both in the Cincinnati area, for 15 years. Geoff is a graduate of Miami University and University of Tulsa (Oklahoma).
Tyler Allchin, Director of Healthcare, JobsOhio
Tyler Allchin is the Director of Healthcare at JobsOhio, the state of Ohio’s private economic development entity. The JobsOhio healthcare team works to grow the sector around the state’s world-class care providers, research institutions, and corporate leaders. Previously, Tyler led strategic development projects for BioEnterprise, Cleveland’s life science accelerator and industry convener. An attorney and former healthcare industry lobbyist, Tyler is a graduate of The University of Akron (JD, MPA) and Kent State University (BA). Tyler lives in the Ohio City neighborhood of Cleveland, Ohio with his wife, Juliana, a Cleveland metro kindergarten teacher. Outside of work, Tyler is the co-founder and chair of The Warren A. Sill Fund, a non-profit organization dedicated to investing in innovative early childhood education programming.
Joseph E. Berger, Senior Vice President, Commercial Business, Battelle
Joe Berger is Senior Vice President, Commercial Business in Battelle’s Contract Research Division. During his decade at Battelle, Joe has also served as the Vice President and General Manager of the Health and Consumer Products Business Unit, as well as roles in Sales, Business Development and Operations Management. Joe’s career has focused on sales, marketing, sales management and general management of highly technical products and services. His industry experience includes working with companies in the specialty chemicals, food ingredients, semiconductor capital equipment and industrial equipment markets. He has worked for both very large and start-up companies and has spent significant time with customers outside of the U.S., mostly in Asia and Western Europe.
Diane Berry, PhD, SVP, Global Policy, Government & Patient Affairs, Sarepta Therapeutics
Diane joined Sarepta Therapeutics in December 2011 and serves as Vice President, Global Policy, Government & Patient Affairs. She engages policymakers at the federal, state, and local levels, as well as patient advocacy organizations, to advance critical policies related to newborn screening, regulatory policy, and reimbursement and access with a goal of expediting development and patient access to genetic-based therapies for rare diseases. Previously, Dr. Berry served in leadership roles for the federal government, across the legislative and executive branches, overseeing and implementing science and technology and public health activities. She served as a Subcommittee Staff Director and Senior Professional Staff Member for the U.S. House of Representatives Committee on Homeland Security and as Chief Scientist and Senior Biodefense Advisor at the Department of Homeland Security in the Office of Health Affairs. Dr. Berry was also a Senior Science Advisor at McKenna, Long, and Aldridge and a Science and Technology Policy Advisor and Fellow within the Department of Defense through the American Association for the Advancement of Science. She earned her Ph.D. in chemical engineering from Northwestern University and received her B.S. and M.S. in chemical/biochemical engineering from Tufts University.
David Breitenbecher, Director of Manufacturing, Alkermes
David Breitenbecher is Director of Manufacturing at Alkermes, located in Wilmington, Ohio. Alkermes seeks to develop innovative medicines that help address the unmet needs and challenges of people living with debilitating diseases. As a fully-integrated, global biopharmaceutical company, Alkermes applies its scientific expertise, proprietary technologies, and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.
Shauna R. Brummet, Ph.D., Bioscience Research & Commercialization Consultant
Dr. Brummet has broad experience in life science research and product development, startup and global companies, innovation and technology commercialization, technology-based economic development, and open innovation. Shauna is highly collaborative and connected in the innovation ecosystem. Development and commercialization of new technology, creation of teams and organizations, public-private partnerships, entrepreneurial coaching, innovation and entrepreneurship in higher education and open innovation are key areas of her expertise. Shauna is a graduate of Purdue University (BS in Microbiology), University of Akron (MS, PhD in Analytical and Biochemistry), and post-doctoral work in molecular biology at The Ohio State University Ohio Agricultural Research & Development Center. Previous employers include The Ohio State University, United States Biochemical, Amersham Life Sciences, Edison Biotechnology Center/BioOhio, NineSigma, and Fluence Therapeutics (founder).
Erica Conroy, Ph.D., Life Sciences focused Senior Executive
Erica Conroy is a results-driven and customer-centric healthcare executive with a passion for developing high-performing teams and solving big problems with innovative solutions. Most recently, Erica served as Senior Vice President, Product, at CoverMyMeds. Before coming onboard with CoverMyMeds, Erica spent five years at Vertex Pharmaceuticals as a medicinal chemist. Erica completed her Bachelor of Science in Biochemistry from California Polytechnic State University, her Ph.D. in Organic Chemistry from The Ohio State University, and continued on to achieve a Post-doctorate in Organic Chemistry from The Scripps Research Institute.
Michael Gaul, President, MJM Management Specialists | Senior Vice President, Operations, Beyond Air
Michael Gaul is a Consultant with MJM Management Specialists. Prior to joining MJM Management Solutions, he was Group Vice President, Manufacturing and Design Services at Sparton Corporation. He has held senior leadership positions in organizations in highly regulated industries including healthcare, military, aerospace and public safety. He has experience with a broad range of products and services including medical devices, diagnostics and reagents, complex electro-mechanical instrumentation, automation, printed circuit board assembly, RF equipment and contract manufacturing and design services. His expertise includes operational excellence, sales and marketing effectiveness, and supply chain, financial and general management. Michael earned his BS in Business Administration from Delaware Valley College and his MBA from Florida Institute of Technology.
Abram is the Executive Director of the Cincinnati Children’s Proton Therapy Center and has served in that capacity since early in the construction process. He brings twelve years of experience in medical and radiation oncology to that role. That experience together with that of being a parent of two daughters has helped frame his efforts in the design and operations of one of the only two proton therapy centers in the world which was designed from the ground up as a pediatric only center. Abram holds a BA and a JD from Boston University.
Stephanie Harrington, MS, CEO, Matrix Medical Devices
Matrix Medical Device founder and visionary, Stephanie Harrington has over 20 years of management experience in the medical device industry, including regulatory affairs, quality system compliance, clinical studies, product development, and commercialization. Guiding startups and established companies alike through new product development and regulatory affairs management is her current mission. Previously, Stephanie served as Chief Operating Officer of Frantz Medical Development, responsible for new product development, manufacturing, and corporate regulatory and quality affairs. Stephanie also served as Vice President and Chief Regulatory Officer at Imalux, establishing the company’s quality system, 510(k) clearances and clinical studies. Prior to Imalux, she was Director, Research and Development at STERIS, responsible for product development of medical device reprocessing systems. Stephanie earned a Masters in Chemical Engineering from Stanford University and holds a BS in Chemical Engineering from the University of Maryland.
Mike Hooven, President and CEO, Enable Injections
Mike has extensive experience in the medical device industry in a broad variety of technical and clinical areas. He is the founder of five medical device companies and holds over 85 issued and pending US patents. Enable Injections is a start-up company focusing on painless injections for vaccines and other drugs. Enable Medical Technologies is a start-up company focusing on opportunities in minimally invasive procedures. Mike is the founder, and a Director of AtriCure, Inc., a medical device company that manufactures and sells surgical devices designed to create precise lesions in soft tissue. He was Director of Product Development at Ethicon Endo-Surgery from 1988 to 1994, and held engineering positions at Siemens/Pacesetter from 1986 to 1988, and at Cordis Corporation from 1981 to 1986. Mike earned a Bachelor of Science in Physics and a Master of Science in Mechanical Engineering from the University of Michigan.
Michelle Leonard, Vice President Global Human Resources, NAMSA
Michelle Leonard joined North American Science Associates (NAMSA) in August 2015 as Director Total Rewards and was named VP, Global Human Resources in April 2019. Michelle is a solution-oriented, forward thinking leader that is committed to collaboration, transparency and solutions that are meaningful to the company and its employees. During her leadership at NAMSA the company has implemented several strategic initiatives to support a total wellness strategy, a global compensation structure and a global HRIS system. Michelle has held progressively responsible positions in Human Resources management within Holcim (US) Inc., Aggregate Industries US, Holcim (Canada) Inc., and HCR Manorcare. She has her Bachelor of Science in Human Resources Management and Services from Bowling Green State University and a MBA in Finance from The University of Toledo.
Peter Mohler, Ph.D., Interim Vice President for Research, Enterprise for Research, Innovation and Knowledge, Chief Scientific Officer for The Ohio State University Wexner Medical Center | Vice Dean for Research, Ohio State College of Medicine | Director, Dorothy M. Davis Heart and Lung Research Institute
Peter Mohler joined The Ohio State University in 2011 as the Director of the Dorothy M. Davis Heart and Lung Research Institute. Prior to this role, Mohler served as Deputy Director of the Diabetes Center and Distinguished Associated Professor of Cardiovascular Medicine at the University of Iowa. He completed his undergraduate work at Wake Forest University, received his PhD from the University of North Carolina, did a Post-doctoral fellowship in the Howard Hughes Medical Institute at Duke University, and held his first faculty appointment at the Vanderbilt University Medical Center. Mohler currently holds multiple NIH extramural grants, is the recipient of honors and awards for his work, serves on national scientific review boards for the US, UK, Italy, France, Belgium, Austria, and Israel, and is on the editorial board for seven journals.
Kristen Parr, General Manager, Cresco Labs
Kristen Parr has a broad understanding of the pharmaceutical industry; specifically in Operations (manufacturing and packaging of both sterile injectable and solid oral dosage products), Supply Chain, Quality, Project Management, Process Development and new drug filings and launches. Kristen has held the titles of VP of Operations Strategy and General Manager of the Wilmington Ohio Alkermes manufacturing facility with a staff of over 500 employees. She led the development and execution of Operations Strategy for Alkermes which includes EHSS, Quality, Supply Chain, and the manufacturing teams. Kristen obtained her B.A. in Chemistry from Indiana University in Bloomington, IN.
Eddie Pauline, President & CEO, BioOhio
Eddie Pauline joined the BioOhio team as President and CEO in August 2021. Read the full announcement here. Eddie previously served as the Director for Economic Development for The Ohio State University within its Enterprise for Research, Innovation, and Knowledge. In this role, Eddie led the economic development and economic impact functions to attract new companies to Ohio and retain and expand Ohio businesses. Working closely with tech transfer and commercialization partners, corporate partnerships, the innovation district, medical center, government affairs, and startup portfolio, he initiated and guided campus-wide and industry-specific workforce, innovation, and placemaking programs to drive economic growth. Prior to coming to Ohio State in 2010, Eddie worked in the digital media industry for startups and large corporations, primarily in Seattle and New York, where he was part of the team that led the successful acquisition of Scout.com by Fox Interactive Media. Eddie holds a BA and a BS from The Ohio State University and an MBA from Franklin University. He is an Ohio Certified Economic Developer. Eddie, his wife Lindsey, and their three children live in Worthington, Ohio.
Eli Phillips, Jr., PharmD, JD, VP, Regulatory Sciences and Insights & Engagement, Cardinal Health
Dr. Phillips is a licensed Pharmacist and Attorney who joined Cardinal Health in June 2014. He serves as Vice-President for Regulatory Sciences and Insights & Engagement within Cardinal Health Specialty Solutions and is responsible for leading all aspects of sales and operations across two business units which provide lifecycle management solutions for the Pharmaceutical and Medical Device industries. These businesses serve over 200 manufacturing clients on their products’ pre-approval and post-commercialization journey by providing expertise in navigating the complex global regulatory approval process and delivering timely insights through commercial provider engagement and HEOR based research.
Dr. Pigott is a recognized leader in medical innovations and vascular surgery. He is founder and president of VentureMed Group, a medical device company involved in the treatment of peripheral artery disease and a founding member of Vascular Innovations, a company devoted to novel technologies for aortic aneurysms. A member of Cleveland Clinic Innovations Commercialization Advisory Board, Dr. Pigott holds his own patents for devices involving aortic aneurysm and peripheral artery technologies. He serves as a consultant to numerous multinational medical device companies and conducts national and regional new device training programs. Dr. Pigott was an early proponent of minimally invasive endovascular treatment for abdominal aortic aneurysms, carotid artery and peripheral artery disease and was a principal investigator for national clinical trials studying these techniques. As a board-certified vascular surgeon at Jobst Vascular Institute (JVI) and ProMedica Toledo Hospital, Dr. Pigott serves as a faculty member of the ACGME-accredited Jobst Vascular Fellowship Program. Dr. Pigott received his medical degree from the Medical College of Ohio, completed his residency at Akron City Hospital, and is fellowship-trained by Mayo Clinic.
Jon Snyder is Chief Executive Officer of Realeve, LLC. Snyder holds nearly 30 years of global management experience in biomedical and healthcare sales, marketing, and operations with significant experience in bringing new products into the marketplace. Snyder is also the founding CEO and an Executive Advisor of Neuros Medical, a Cleveland, Ohio-based medical device company, which he led through the past several years of development, raising $35 million in venture capital and strategic partner investment. His background covers business development, product development, market management, sales management, venture capital investment, and fundraising at start-up and Fortune 500 (Top 20) companies including Cyberonics, Cardinal Health, Imalux, and STERIS. Snyder has a B.S. from Ohio University.
Stacy Strauss, Director, Ohio University Innovation Center
Stacy Strauss joined the Innovation Center as the Associate Director in August 2014 and was promoted to Director in October 2016. Ms. Strauss manages the staff, makes connections for clients, oversees facility management, fundraising efforts, budget analysis, grant writing, and other Innovation Center operations. During her tenure, the Innovation Center has been named the Incubator of the Year (2019) by the leading international professional association; the Rural Incubator of the Year twice (2016 and 2019); and was ranked by a global benchmarking institute as the 3rd best university incubator in North America (2016). She has secured over $3.4 million in grants to support the work of the Innovation Center. Ms. Strauss joined the Innovation Center from Hocking College, where she served in a dual role as a Student Affairs Coordinator and Career Services Director from April 2013 through August 2014. Ms. Strauss holds a bachelor’s degree in history from Kenyon College and a master’s degree in education from Ohio State University. She also holds a Business Incubator Management certificate from the International Business Innovation Association.
Michael Triplett, Ph.D., President & CEO, Armatus Bio
Dr. Triplett is the President & CEO of Armatus Bio, as well as Co-Founder of Clarametyx Biosciences, a Columbus, Ohio-based company building a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections associated with biofilms. Mike is also President of Carmen Partners LLC, a life science ventures, commercialization, and innovation consultancy. Dr. Triplett co-founded and served as President and CEO of Myonexus Therapeutics. Prior to co-founding Myonexus Therapeutics, Dr. Triplett served as Chief Executive Officer of N8 Medical, a clinical stage combination device company with Breakthrough designation for its lead antimicrobial endotracheal tube product. Dr. Triplett is currently leading the InnovateOhio Life Sciences Working Group for Ohio Lieutenant Governor Jon Husted with the mission to propose a life sciences economic development strategy for the State of Ohio. Dr. Triplett received his BS in Chemical Engineering (summa cum laude) and PhD in Chemical Engineering from The Ohio State University.
Bert G. Wickey, Director, Healthcare Policy and Advocacy – Strategic Customer Group, Johnson & Johnson
Bert Wickey is a Healthcare Policy & Advocacy Director representing the Janssen Pharmaceutical Inc. sector for Johnson & Johnson in Ohio & Kentucky. Janssen currently promotes 22 products in six therapeutic areas including Cardiovascular & Metabolism, Immunology, Infectious Diseases, Neuroscience and Oncology. In his 30th year at Johnson and Johnson, he has experience in various roles including sales, sales management, contracting with commercial & government payers, and policy & advocacy. Over the past 10 years, his role has focused on engaging provider and patient advocacy organizations at the state & national level regarding appropriate access to treatment and preserving the provider/patient decision making process. Bert is a graduate of California State University – Sacramento, CA and has resided in Medina, OH for the past 22 years.